Protease-Cleavable Polypeptides for Tissue-Selective Drug Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to identify new substrates for proteases that can be used in therapeutic, diagnostic, and prophylactic applications, particularly in diseases where protease activity is dysregulated, such as cancer and autoimmune disorders, to enhance therapeutic efficacy and reduce systemic toxicities.
Innovation Solution
Development of polypeptides comprising a cleavable moiety (CM) that serves as a substrate for proteases like MMPs, which are specifically activated in diseased tissues, allowing for the creation of activatable molecules with therapeutic, diagnostic, or imaging agents, and are designed to minimize activation in healthy tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protease substrates are used to activate therapeutic molecules in diseased tissues, then therapeutic efficacy is enhanced through targeted activation, but systemic toxicities may occur due to off-target cleavage in healthy tissues
Solution Approach 1:
The patent applies local quality by designing substrates with specific amino acid sequences (e.g., GPLGVR, GPLGI) that are selectively recognized and cleaved by proteases overexpressed in diseased tissues such as cancer or inflammatory sites. This spatial specificity ensures that therapeutic activation occurs locally at the disease site rather than systemically, thereby enhancing therapeutic efficacy while minimizing off-target toxicities in healthy tissues
Solution Approach 2:
The patent employs parameter changes by optimizing substrate sequences to achieve differential cleavage rates between diseased and healthy tissues. By selecting specific amino acid compositions and sequences, the substrates exhibit high cleavability (e.g., >50% conversion) in protease-rich diseased environments while maintaining stability in normal physiological conditions, thus enabling selective activation and reducing systemic toxicity
2Productivity
If protease substrates are designed for high cleavability in diseased tissues, then activation efficiency is improved, but selectivity between diseased and healthy tissues may be compromised
Solution Approach 1:
The patent achieves both high activation efficiency and tissue selectivity by designing substrates with localized recognition sequences that match the specific protease profile of diseased tissues. Examples include substrates cleaved by MMP-2, MMP-9, or cathepsin B that are overexpressed in cancer or inflammatory conditions, ensuring rapid activation (high productivity) at the target site while maintaining stability in healthy tissues (high selectivity)
Solution Approach 2:
The patent applies inversion by designing substrates that are stable under normal physiological conditions but undergo rapid cleavage only in the presence of disease-associated proteases. This inverted behavior pattern—stability in healthy tissues and activation in diseased tissues—enables the substrate to achieve both high activation efficiency at the target and high tissue selectivity
3Device complexity
If small molecule substrates are used for protease cleavage, then molecular simplicity is maintained, but therapeutic potency may be insufficient compared to macromolecular agents
Solution Approach 1:
The patent applies merging by conjugating small molecule substrates with therapeutic macromolecules such as antibodies, cytokines, or imaging agents. The small molecule substrate serves as a cleavable linker or activation trigger that, upon protease cleavage, releases or activates the attached potent therapeutic agent. This combination maintains the simplicity and targetability of small molecules while incorporating the high therapeutic potency of macromolecular agents
Solution Approach 2:
The patent uses segmentation by dividing the therapeutic construct into modular components: a protease-cleavable substrate segment, a linker segment, and a therapeutic payload segment. The substrate segment (e.g., GPLGVR sequence) is designed for specific protease recognition, while the payload segment contains the high-potency therapeutic agent. This segmented architecture allows the simple substrate to trigger activation of a complex, potent therapeutic molecule
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptides provide targeted activation in diseased tissues, enhancing therapeutic efficacy while reducing systemic toxicities and improving the therapeutic index by leveraging the unique protease activity profiles of different disease types.
Implementation Method 1
Proteases are enzymes that catalyze the hydrolysis of peptide bonds between amino acid residues. Some proteases are known to break specific peptide bonds based on the presence of a particular amino acid sequence within a protein.
Data Source
AI summary
Isolated polypeptides that include a cleavable moiety that is a substrate for at least one protease (e.g., MMP) are disclosed. Activatable molecules including the isolated polypeptides are disclosed. Methods of making and using the isolated polypeptides and activatable molecules including the isolated polypeptides in a variety of therapeutic, diagnostic, and prophylactic applications are disclosed.